Current diagnostics and therapy for carcinomas of the bilary tree and gallbladder;Aktuelle diagnostik und therapie von gallengangs- und gallenblasenkarzinomen

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 3, 2005, Pages 305-315

  Wiedmann, Marcus ^a   Schoppmeyer, K ^a   Witzigmann, H ^a   Hauss, J ^a   Mossner J ^a   Caca, K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Ampulla Vateri carcinoma; Diagnosis; Gallbladder cancer; Hilar cholangiocarcinoma; Intrahepatic cholangiocarcinoma; Therapy

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

BILE DUCT CARCINOMA; BILE DUCT PROSTHESIS; BILE DUCT STENT; BILIARY TRACT CANCER; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CARCINOGENESIS; CHOLANGIOGRAPHY; ECHOGRAPHY; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; GENE MUTATION; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; KLATSKIN TUMOR; MAGNETIC RESONANCE CHOLANGIOGRAPHY; MAGNETIC RESONANCE TOMOGRAPHY; MALIGNANT TRANSFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; RARE DISEASE; REVIEW; STENT; TOMOGRAPHY; VATER PAPILLA CARCINOMA;

ALGORITHMS; AMPULLA OF VATER; BILE DUCT NEOPLASMS; BILE DUCTS; BILE DUCTS, INTRAHEPATIC; BIOPSY; BRACHYTHERAPY; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; COMMON BILE DUCT NEOPLASMS; CYCLOOXYGENASE INHIBITORS; GALLBLADDER; GALLBLADDER NEOPLASMS; HEPATECTOMY; HEPATIC DUCT, COMMON; HUMANS; KLATSKIN'S TUMOR; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PALLIATIVE CARE; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS;

EID: 16244388921     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813319     Document Type: Review

References (153)

1. de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378
2. Taylor-Robinson SD, Toledano MB, Arora S et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820
3. Jean M, Dua K. Tumors of the ampulla of Vater. Curr Gastroenterol Rep 2003; 5: 171-175
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357
5. Khan SA, Taylor-Robinson SD, Toledano MB et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813
6. Davila JA, El-Serag HB. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol 2002; 97: 3199-3200
7. Redaelli CA, Buchler MW, Schilling MK et al. High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery 1997; 121: 58-63
8. Chow WH, Johansen C, Gridley G et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79: 640-644
9. Okamoto M, Okamoto H, Kitahara F et al. Ultrasonographic evidence of association of polyps and stones with gallbladder cancer. Am J Gastroenterol 1999; 94: 446-450
10. Aldridge MC, Bismuth H. Gallbladder cancer: the polyp-cancer sequence. Br J Surg 1990; 77: 363-364
11. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10 (Suppl 4): 308-311
12. Tocchi A, Mazzoni G, Liotta G et al. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg 2001; 234: 210-214
13. Bettschart V, Clayton RA, Parks RW et al. Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease. Gut 2002; 51: 128-129
14. Tomimatsu M, Ishiguro N, Taniai M et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993; 72: 683-688
15. Pauli RM, Pauli ME, Hall JG. Gardner syndrome and periampullary malignancy. Am J Med Genet 1980; 6: 205-219
16. Gouma DJ, Obertop H, Vismans J et al. Progression of a benign epithelial ampullary tumor to adenocarcinoma. Surgery 1987; 101: 501-504
17. Lazcano-Ponce EC, Miquel JF, Munoz N et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-364
18. Misra S, Chaturvedi A, Goel MM et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 2000; 26: 164-167
19. Ahrendt SA, Rashid A, Chow JT et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000; 7: 426-431
20. Chow NH, Huang SM, Chan SH et al. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 1995; 15: 1055-1059
21. Furubo S, Harada K, Shimonishi T et al. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999; 35: 230-240
22. Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 1999; 29: 1453-1462
23. Sturm PD, Baas IO, Clement MJ et al. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. Int J Cancer 1998; 78: 695-698
24. Bergquist A, Glaumann H, Stal P et al. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med 2001; 249: 69-75
25. Della Torre G, Pasquini G, Pilotti S et al. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol 2000; 9: 41-46
26. Fiorentino M, D'Errico A, Altimari A et al. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol 1999; 8: 189-194
27. Harnois DM, Que FG, Celli A et al. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997; 26: 884-890
28. Tannapfel A, Weinans L, Geissler F et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 2000; 45: 317-324
29. Tullo A, D'Erchia AM, Honda K et al. New p53 mutations in hilar cholangiocarcinoma. Eur J Clin Invest 2000; 30: 798-803
30. Caca K, Feisthammel J, Klee K et al. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 2002; 97: 481-488
31. Ahrendt SA, Eisenberger CF, Yip L et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999; 84: 88-93
32. Horie S, Endo K, Kawasaki H et al. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch 2000; 437: 25-30
33. Tannapfel A, Benicke M, Katalinic A et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47: 721-727
34. Ito Y, Takeda T, Sasaki Y et al. Expression of Fas and Fas ligand reflects the biological characteristics but not the status of apoptosis of intrahepatic cholangiocellular carcinoma. Int J Mol Med 2000; 6: 581-586
35. Que FG, Phan VA, Phan VH et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999; 30: 1398-1404
36. Shimonishi T, Isse K, Shibata F et al. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000; 32: 761-769
37. Yoon JH, Werneburg NW, Higuchi H et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002; 62: 6500-6505
38. Chariyalertsak S, Sirikulchayanonta V, Mayer D et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001; 48: 80-86
39. Sirica AE, Lai GH, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potenzial therapeutic strategies. J Gastroenterol Hepatol 2001; 16: 363-372
40. Yoon JH, Higuchi H, Werneburg NW et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122: 985-993
41. Caplin M, Khan K, Savage K et al. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol 1999; 30: 519-526
42. Ito Y, Miyoshi E, Takeda T et al. ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 2000; 58: 248-252
43. Harada K, Zen Y, Kanemori Y et al. Human REG I gene is up-regulated in intrahepatic cholangiocarcinoma and its precursor lesions. Hepatology 2001; 33: 1036-1042
44. Lavaissiere L, Jia S, Nishiyama M et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996; 98: 1313-1323
45. Terada T, Ueyama J, Ukita Y et al. Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, hepatolithiasis and intrahepatic cholangiocarcinoma. Liver 2000; 20: 450-457
46. Itoi T, Shinohara Y, Takeda K et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000; 52: 380-386
47. Endo K, Ashida K, Miyake N et al. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol 2001; 193: 310-317
48. Rashid A, Gao YT, Bhakta S et al. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001; 61: 3406-3409
49. Kang YK, Kim WH, Lee HW et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79: 477-483
50. Kawahara N, Ono M, Taguchi K et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998; 28: 1512-1517
51. Jaiswal M, LaRusso NF, Burgart LJ et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190
52. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G626-G634
53. Torok NJ, Higuchi H, Bronk S et al. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res 2002; 62: 1648-1653
54. Ramage JK, Donaghy A, Farrant JM et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865-869
55. Patel AH, Harnois DM, Klee GG et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204-207
56. Hultcrantz R, Olsson R, Danielsson A et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669-673
57. Nichols JC, Gores GJ, LaRusso NF et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993; 68: 874-879
58. Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 7-11
59. Hann LE, Schwartz LH, Panicek DM et al. Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment. Radiology 1998; 206: 651-656
60. Fulcher AS, Turner MA. MR cholangiopancreatography. Radiol Clin North Am 2002; 40: 1363-1376
61. Yeh TS, Jan YY, Tseng JH et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 2000; 95: 432-440
62. Zidi SH, Prat F, Le Guen O et al. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 2000; 46: 103-106
63. Manfredi R, Brizi MG, Masselli G et al. Malignant biliary hilar stenosis: MR cholangiography compared with direct cholangiography. Radiol Med (Torino) 2001; 102: 48-54
64. Lopera JE, Soto JA, Munera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220: 90-96
65. Adamek HE, Albert J, Weitz M et al. A prospective evaluation of magnetic resonance cholangiopancreatography in patients with suspected bile duct obstruction. Gut 1998; 43: 680-683
66. Angulo P, Pearce DH, Johnson CD et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000; 33: 520-527
67. Nesbit GM, Johnson CD, James EM et al. Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography. AJR Am J Roentgenol 1988; 151: 933-938
68. Cannon ME, Carpenter SL, Elta GH et al. EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. Gastrointest Endosc 1999; 50: 27-33
69. Kubo H, Chijiiwa Y, Akahoshi K et al. Pre-operative staging of ampullary tumours by endoscopic ultrasound. Br J Radiol 1999; 72: 443-447
70. Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl 6): VI1-9
71. Rumalla A, Baron TH, Leontovich O et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Mayo Clin Proc 2001; 76: 29-33
72. Klump B, Hsieh CJ, Dette S et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 2003; 9: 1773-1778
73. Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 1990; 36: 588-592
74. Ronchon T, Berger F, Chavaillon A et al. Contribution of endoscopy to diagnosis and treatment of tumors of the ampulla of Vater. Cancer 1989; 64: 161-167
75. Kluge R, Schmidt F, Caca K et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33: 1029-1035
76. Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28: 700-706
77. Fujita N, Noda Y, Kobayashi G et al. Staging of bile duct carcinoma by EUS and IDUS. Endoscopy 1998; 30 (Suppl 1): A132-A134
78. Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517, discussion 517-519
79. Sobin LH, Wittekind C (eds). UICC: TNM Classification of Malignant Tumors. 6th ed. Wiley-Liss. New York, 2002: 74-85
80. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38
81. Casavilla FA, Marsh JW, Iwatsuki S et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185: 429-436
82. Busuttil RW, Farmer DG. The surgical treatment of primary hepatobiliary malignancy. Liver Transpl Surg 1996; 2: 114-130
83. Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473, discussion 473-475
84. Wall WJ. Liver transplantation for hepatic and biliary malignancy. Semin Liver Dis 2000; 20: 425-436
85. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637
86. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137
87. Birkmeyer JD, Stukel TA, Siewers AE et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117-2127
88. Madoff DC, Hicks ME, Abdalla EK et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness - study in 26 patients. Radiology 2003; 227: 251-260
89. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88: 165-175
90. Sewnath ME, Karsten TM, Prins MH et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2002; 236: 17-27
91. Kawasaki S, Imamura H, Kobayashi A et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003; 238: 84-92
92. Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996224: 628-638
93. Neuhaus P, Jonas S, Bechstein WO et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230: 808-818, discussion 819
94. Hadjis NS, Blenkharn JI, Alexander N et al. Outcome of radical surgery in hilar cholangiocarcinoma. Surgery 1990; 107: 597-604
95. Seyama Y, Kubota K, Sano K et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 2003; 238: 73-83
96. Gerhards MF, van Gulik TM, de Wit LT et al. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma - a single center experience. Surgery 2000; 127: 395-404
97. Huang ZQ, Zhou NX, Wang DD et al. Changing trends of surgical treatment of hilar bile duct cancer: clinical and experimental perspectives. World J Gastroenterol 2000; 6: 777-782
98. Madariaga JR, Iwatsuki S, Todo S et al. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998; 227: 70-79
99. Iwatsuki S, Todo S, Marsh JW et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 358-364
100. Tashiro S, Tsuji T, Kanemitsu K et al. Prolongation of survival for carcinoma at the hepatic duct confluence. Surgery 1993; 113: 270-278
101. Pitt HA, Nakeeb A, Abrams RA et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995; 221: 788-797, discussion 797-798
102. Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998; 34: 977-986
103. Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003; 97: 2783-2790
104. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969
105. Posner S, Colletti L, Knol J et al. Safety and long-term efficacy of transduodenal excision for tumors of the ampulla of Vater. Surgery 2000; 128: 694-701
106. Witzigmann H, Mobius C, Uhlmann D et al. Behandlungskonzept von Adenomen der Papilla Vateri. Chirurg 2000; 71: 196-201
107. Catalano MF, Linder JD, Chak A et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 2004; 59: 225-232
108. Norton ID, Gostout CJ, Baron TH et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56: 239-243
109. Bertoni G, Sassatelli R, Nigrisoli E et al. Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma. Endoscopy 1997; 29: 685-688
110. Binmoeller KF, Boaventura S, Ramsperger K et al. Endoscopic snare excision of benign adenomas of the papilla of Vater. Gastrointest Endosc 1993; 39: 127-131
111. Neoptolemos JP, Talbot IC, Carr-Locke DL et al. Treatment and outcome in 52 consecutive cases of ampullary carcinoma. Br J Surg 1987; 74: 957-961
112. Yamaguchi K, Chijiiwa K, Saiki S et al. Retrospective analysis of 70 operations for gallbladder carcinoma. Br J Surg 1997; 84: 200-204
113. Gerhardt T, Mey U, Sauerbruch T et al. Palliative Therapie des inoperablen Gallengangskarzinoms. Dtsch Med Wochenschr 2002; 127: 1835-1839
114. Nordback IH, Pitt HA, Coleman J et al. Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 1994; 115: 597-603
115. Smith AC, Dowsett JF, Russell RC et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
116. Speer AG, Cotton PB, Russell RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
117. Doctor N, Dick R, Rai R et al. Results of percutaneous plastic stents for malignant distal biliary obstruction following failed endoscopic stent insertion and comparison with current literature on expandable metallic stents. Eur J Gastroenterol Hepatol 1999; 11: 775-780
118. Lammer J, Neumayer K. Biliary drainage endoprostheses: experience with 201 placements. Radiology 1986; 159: 625-629
119. Mueller PR, Ferrucci JT Jr, Teplick SK et al. Biliary stent endoprosthesis: analysis of complications in 113 patients. Radiology 1985; 156: 637-639
120. Halm U, Schiefke I, Fleig WE et al. Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stents: a prospective, randomized trial. Endoscopy 2001; 33: 491-494
121. Barrioz T, Ingrand P, Besson I et al. Randomised trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin. Lancet 1994; 344: 581-582
122. Ghosh S, Palmer KR. Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid. Gut 1994; 35: 1757-1759
123. Lammer J, Stoffler G, Petek WW et al. In vitro long-term perfusion of different materials for biliary endoprostheses. Invest Radiol 1986; 21: 329-331
124. Lammer J, Hausegger KA, Fluckiger F et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 1996; 201: 167-172
125. Prat F, Chapat O, Ducot B et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998; 47: 1-7
126. Knyrim K, Wagner HJ, Pausch J et al. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 1993; 25: 207-212
127. Wagner HJ, Knyrim K, Vakil N et al. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 199325: 213-218
128. Tham TC, Carr-Locke DL, Vandervoort J et al. Management of occluded biliary Wallstents. Gut 1998; 42: 703-707
129. Deviere J, Baize M, de Toeuf J et al. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988; 34: 95-101
130. Polydorou AA, Cairns SR, Dowsett JF et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 1991; 32: 685-689
131. De Palma GD, Galloro G, Siciliano S et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553
132. De Palma GD, Pezzullo A, Rega M et al. Unilateral placement of metallic stents for malignant hilar obstruction: A prospective study. Gastrointest Endosc 2003; 58: 50-53
133. Ortner MA, Liebetruth J, Schreiber S et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998; 114: 536-542
134. Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31: 291-298
135. Ortner MEJ, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363
136. Dumoulin FL, Gerhardt T, Fuchs S et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57: 860-867
137. Bowling TE, Galbraith SM, Hatfield AR et al. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996; 39: 852-855
138. Kamada T, Saitou H, Takamura A et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34: 767-774
139. Mittal B, Deutsch M, Iwatsuki S. Primary cancers of extrahepatic biliary passages. Int J Radiat Oncol Biol Phys 1985; 11: 849-854
140. Eschelman DJ, Shapiro MJ, Bonn J et al. Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology 1996; 200: 717-724
141. Rumalla A, Baron TH. Evaluation and endoscopic palliation of cholangiocarcinoma. Management of cholangiocarcinoma. Dig Dis 1999; 17: 194-200
142. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600
143. Schiefke I, Zabel-Langhennig A, Wiedmann M et al. Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc 2003; 58: 213-219
144. Chaudhary A, Dhar P, Tomey S et al. Segment III cholangiojejunostomy for carcinoma of the gallbladder. World J Surg 1997; 21: 866-870, discussion 870-871
145. Kapoor VK, Pradeep R, Haribhakti SP et al. Intrahepatic segment III cholangiojejunostomy in advanced carcinoma of the gallbladder. Br J Surg 1996; 83: 1709-1711
146. Patt YZ, Jones DV Jr, Hoque A et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14: 2311-2315
147. Castro MP. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer 1998; 82: 639-641
148. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2: 1245-1248
149. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21
150. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952
151. Wiedmann M, Kreth F, Feisthammel J et al. Imatinib mesylate (ST1571; Glivec) - a new approach in the treatment of biliary tract cancer? Anticancer Drugs 2003; 14: 751-760
152. Feisthammel J, Wiedmann M, Kreth F et al. EGFR Expression und der Effekt von Gefitinib auf das in-vitro Wachstum von Tumoren der Gallenwege. Z Gastroenterol 2004; 42: 77A
153. Date K, Matsumoto K, Kuba K et al. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998; 17: 3045-3054